Calls for papers
-
Arikace developer Insmed Incorporated has appointed Will Lewis, co-founder of Aegerion Pharmaceuticals, to succeed Tim Whitten as President and Chief Executive Officer. According to the company, Whitten has resigned from the board of directors as… Read more . . .
-
Teva has filed a lawsuit in the US District Court for the District of Delaware against Perrigo and Catalent after Perrigo filed an ANDA for a generic version of Teva’s ProAir HFA albuterol sulfate MDI.… Read more . . .
-
Civitas Therapeutics has appointed Bryan Stuart as Chief Business Officer. Civitas, which was spun off from Alkermes, is developing carrier-free inhaled drugs based on its ARCUS particle engineering platform and inhaler. The company’s lead candidate… Read more . . .
-
The Anti-Infective Drugs Advisory Committee (AIDAC) of the FDA voted 13 to 1 in favor of approval of Novartis’s tobramycin inhalation powder (TIP) for the treatment of P. aeruginosa-infected cystic fibrosis patients six years old… Read more . . .
-
The FDA has approved a generic equivalent to Meda’s Astepro, an azelastine nasal spray, 0.1876MG, manufactured by Apotex. Meda filed a patent infringement suit in January 2012 after Apotex submitted its ANDA. The two companies… Read more . . .
-
According to Boehringer Ingelheim, a combination of tiotropium and olodaterol delivered using the Respimat soft mist inhaler significantly improved 24-hour FEV1 in COPD patients compared to olodaterol monotherapy at all doses tested. The 4-week double-blind… Read more . . .
-
The United States Patent and Trademark Office has issued a method of treatment patent to Aradigm for its inhaled nicotine formulations. US Patent No. 8,256,433, for Systems and Methods for Effecting Cessation of Tobacco Use,… Read more . . .
-
Rigel Pharmaceuticals says that it has begun a Phase 2 clinical study of its R343 nhaled SYK inhibitor that is being evaluated as a potential treatment for allergic asthma. The 8-week study, called SITAR (SYK… Read more . . .
-
Almirall has opened a new affiliate in Toronto, Canada. Having a presence in Canada will help the company roll out its recently approved aclidinium DPI for COPD, among other drugs, Almirall says. The company will… Read more . . .
-
A study by the Childhood Asthma Management Program (CAMP) Research Group published online in the New England Journal of Medicine on September 3 finds that children who received 400 μg of inhaled budesonide daily for… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan